MarketVIEW Chronic Disease Vaccines  ·  Feb 2017 edition

Therapeutic Cancer
Vaccines Forecast

Cancer immunotherapy has moved from a handful of speculative approaches to one of oncology's most active research fields, and therapeutic cancer vaccines sit at its historic core. Provenge (sipuleucel-T) remains the only therapeutic cancer vaccine ever approved, PROSTVAC's pivotal Phase 3 trial was ruled futile and discontinued, yet mRNA technology has since triggered a genuine renaissance: Moderna and Merck's individualized neoantigen therapy is now in registrational Phase 3 testing in melanoma, and BioNTech's autogene cevumeran is showing multi-year immune persistence in pancreatic cancer. This is the independent, program-level competitive landscape analysis of where the field stands now, drawing on VacZine Analytics' long standing expertise in chronic disease vaccine markets.

9.7M Cancer Deaths a Year Worldwide mRNA-4157/V940 Now in Phase 3 300+ Programs Tracked, Global Provenge: First-Ever Approved, 2010
Product catalogue
VAMV072
Feb 2017 edition

Format
Executive presentation + Excel workbook
Coverage
Global, 300+ program landscape
Forecast horizon
To 2035
Approach
Phase I-III program-level competitive landscape analysis
Base edition
Feb 2017
Availability
Syndicated / bespoke
20M
New cancer cases worldwide
a year (GLOBOCAN 2022)
9.7M
Cancer deaths worldwide
a year (GLOBOCAN 2022)
300+
Cancer vaccine programs
tracked, Phase I-III
49%
Reduction in melanoma recurrence/
death risk, mRNA-4157/V940 + Keytruda
Disease background

From Provenge to the neoantigen era

Cancer immunotherapy has become the most closely watched strategy in oncology drug development, and therapeutic cancer vaccines were among its earliest, most difficult proving grounds. Understanding why the field's two founding programs took such different paths, and what mRNA technology has since made possible, is central to understanding what the current wave of candidates could be worth.

GLOBOCAN 2022, WHO/IARC & 2025/26 pipeline data

Cancer immunotherapy overview - mechanisms, burden and the vaccine category

Cancer remains one of the leading causes of death worldwide. GLOBOCAN 2022, the most recent complete global estimate from the WHO's International Agency for Research on Cancer, records 20 million new cancer cases and 9.7 million cancer deaths worldwide in a single year, against a lifetime risk of dying from cancer of roughly 1 in 9 for men and 1 in 12 for women. That is a marked rise on the 2012 WHO figures this report's original 2017 edition was built around, 8.2 million deaths and 14 million new cases that year, and on unchanged trends GLOBOCAN now projects more than 35 million new cancer cases a year by 2050, a 77% increase on 2022, with the steepest proportional rises concentrated in lower and middle Human Development Index countries. The scale of that growing burden is the enduring commercial rationale for every approach described below.

Cancer immunotherapy, broadly split into active and passive strategies, aims to harness the body's own immune system against tumour progression, and has become the most promising search for novel cancer therapies of the past two decades. Passive approaches supply ready-made immune effectors from outside the body: tumour-specific or bi-specific monoclonal antibodies, and adoptive cell therapies such as CAR-T, which re-engineer a patient's own T cells to recognise tumour antigens directly. Active approaches instead aim to train the patient's own immune system to do the work: checkpoint inhibitors (targeting CTLA-4 or the PD-1/PD-L1 axis) release the brakes the tumour has placed on existing T-cell activity, while therapeutic cancer vaccines, built from peptides, dendritic cells, allogenic or autologous cells, viral vectors, oncolytic viruses or, most recently, mRNA, aim to actively prime new, tumour-specific T-cell responses from scratch. That distinction from a prophylactic vaccine matters: a therapeutic candidate must recognise and destroy cells that are already transformed, not simply prevent new infection or transformation, which is why the category has historically been so much harder to deliver than prophylactic vaccination.

Dendreon's Provenge (sipuleucel-T) was the first, and remains the only, therapeutic cancer vaccine ever approved for any cancer, an autologous dendritic cell therapy cleared by the FDA in April 2010 for asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. Its commercial life has been unusually turbulent for an approved oncology product: Dendreon itself filed for bankruptcy in 2014, and ownership has changed hands repeatedly since, from Valeant to China's Sanpower Group in 2017 and on to the retail-linked Cenbest around 2023, yet Provenge continues to be manufactured and marketed today from Dendreon's Union City, Georgia facility. PROSTVAC, Bavarian Nordic's vaccinia/fowlpox-vectored candidate targeting PSA and partnered with Bristol-Myers Squibb, told the opposite story: an independent Data Monitoring Committee ruled in September 2017 that its pivotal Phase 3 PROSPECT trial in metastatic castration-resistant prostate cancer was futile, ending a six-year development odyssey, costing Bavarian Nordic close to a billion dollars in unrealised BMS milestones, and standing for years afterward as the field's cautionary case study.

It is against that founding history, one approval and one high-profile failure, that the current mRNA-driven renaissance stands out. Moderna and Merck's individualized neoantigen therapy, mRNA-4157/V940 (now named intismeran autogene), combined with pembrolizumab, has shown a sustained reduction in recurrence or death of around 49% versus pembrolizumab alone at five-year follow-up in resected high-risk melanoma, and has moved into global registrational Phase 3 testing in both adjuvant melanoma and non-small-cell lung cancer. BioNTech's autogene cevumeran, developed with Memorial Sloan Kettering and Genentech, is showing multi-year persistence of tumour-specific CD8 T-cell memory in resected pancreatic cancer, historically one of the hardest tumour types to treat, and has progressed into a randomised Phase 2 trial. The renaissance has not been without its own attrition, Gritstone Bio filed for Chapter 11 bankruptcy in October 2024 after its own neoantigen candidate missed a Phase 2 colorectal cancer endpoint, and Genocea Biosciences wound down in 2022, but the depth and quality of the current clinical data mark a genuine inflection point for the category.

2026 20M new cancer cases/year  |  9.7M deaths/year  |  300+ programs tracked  |  mRNA-4157/V940 now in Phase 3 (melanoma & NSCLC)
Product & competitor landscape

From one approval and one failure to a crowded neoantigen field

This report's underlying model tracks more than 300 verified cancer vaccine programs across Phase I-III, delineated by sponsor, sponsor type, mechanism, tumour type and results. The six programs below illustrate the field's arc, from Provenge and the discontinued PROSTVAC through to the mRNA-driven candidates now defining the category.

  • Dendreon (Cenbest)Approved 2010, still marketed
    Provenge (sipuleucel-T) Autologous dendritic cell, anti-PAP
    The first, and to date only, therapeutic cancer vaccine ever approved for any cancer, cleared by the FDA in 2010 for metastatic castration-resistant prostate cancer. Ownership has passed from Valeant to Sanpower and on to Cenbest, but manufacturing continues uninterrupted at Dendreon's Georgia facility.
  • Bavarian Nordic / Bristol-Myers SquibbPhase 3 PROSPECT discontinued, 2017
    PROSTVAC Vaccinia/fowlpox-vectored, anti-PSA
    An independent Data Monitoring Committee ruled the pivotal Phase 3 PROSPECT trial in metastatic castration-resistant prostate cancer futile in September 2017; Bristol-Myers Squibb did not exercise its opt-in rights, ending the field's highest-profile prior late-stage programme.
  • Moderna / MerckPhase 3 INTerpath-001 met primary endpoint, Aug 2026
    mRNA-4157/V940 (intismeran autogene) Individualized neoantigen therapy, mRNA
    Combined with pembrolizumab, five-year KEYNOTE-942 follow-up data had shown a sustained reduction in melanoma recurrence or death of around 49% versus pembrolizumab alone. On 19 August 2026, Merck and Moderna announced that the registrational Phase 3 INTerpath-001 trial (n=1,137, resected Stage IIB-IV melanoma) met its primary endpoint of recurrence-free survival and the key secondary endpoint of distant metastasis-free survival versus pembrolizumab alone, with no new safety signals reported; a companion Phase 3 trial in non-small-cell lung cancer continues to recruit, and the companies say they are engaging regulators on filing submissions.
  • BioNTech / Genentech-Roche / MSKPhase 2 colorectal trial halted, Aug 2026
    Autogene cevumeran Individualized neoantigen mRNA lipoplex
    Six-year Phase 1 follow-up data (AACR 2026) show durable, functional CD8 T-cell memory correlating with exceptional survival in resected pancreatic cancer responders. BioNTech halted its randomised Phase 2 trial of autogene cevumeran monotherapy in resected, ctDNA-positive colorectal cancer in late August 2026 after an independent monitoring committee found the trial unlikely to show efficacy and flagged a numerical overall-survival imbalance; the separate Phase 2 pancreatic cancer trial, combined with atezolizumab, continues, having previously been discontinued in urothelial carcinoma.
  • BioNTechPhase 2/3 AHEAD-MERIT missed PFS, Oct 2026
    BNT113 HPV16-targeted mRNA vaccine
    BioNTech's BNT113, an mRNA vaccine targeting HPV16-positive head and neck cancer, missed the progression-free survival primary endpoint in the pivotal Phase 2/3 AHEAD-MERIT trial, reported 13 October 2026; the trial continues toward its second primary endpoint of overall survival.
  • Transgene / NECPhase I/II, recruiting
    TG4050 Individualized neoantigen vaccine
    In head and neck cancer, all 16 Phase 1 patients treated with TG4050 remained disease-free at 24.1-month follow-up, against three relapses among 16 in the observation control arm. The randomised Phase 2 portion has been enrolling internationally since June 2024. In June 2026, Transgene also initiated a second myvac®-platform candidate, TG4070, in a randomised Phase 1 trial combined with nivolumab in resected non-small-cell lung cancer patients who did not achieve a major pathological response to neoadjuvant therapy.
Field inflection point
49% risk cut

The therapeutic cancer vaccine field has moved from one approval and one high-profile failure to a genuinely crowded, mRNA-driven competitive landscape. Moderna and Merck's mRNA-4157/V940 has taken melanoma recurrence risk reduction into registrational Phase 3 testing, BioNTech's autogene cevumeran is showing durable immune memory in pancreatic cancer, and Transgene's TG4050 has posted a striking early disease-free survival signal in head and neck cancer. Provenge remains the field's sole approval and PROSTVAC its cautionary tale, but Gritstone Bio's 2024 bankruptcy and Genocea's 2022 wind-down are reminders that clinical and commercial attrition remain very real, even amid this renaissance. More recently, BioNTech's BNT113 missed its progression-free survival endpoint in head and neck cancer and MimiVax's SurVaxM narrowly missed its Phase 2b overall-survival goal in glioblastoma, both reported in October 2026, yet investor appetite for the category persists: Nouscom closed an oversubscribed $135m Series D in October 2026 to advance its off-the-shelf neoantigen vaccine NOUS-209 into a pivotal Phase 2 trial in Lynch syndrome-associated cancers. The VacZine Analytics model quantifies the commercial opportunity this reshuffled landscape creates across all tracked programs and tumour types.

Scope of analysis

Six analytical layers - one commercial picture

This is a genuinely comprehensive, global program-level review, spanning disease burden, cancer immunotherapy dynamics, the full R&D competitive landscape and Phase III case-study analysis across more than 300 tracked programs to 2035.

Global program-level landscape review

Analysis of over 300 verified cancer vaccine programs across Phase I-III, delineated by sponsor, sponsor type, mechanism, tumour type and results.

Competitor & pipeline review

Full review by mechanism and tumour type, from Provenge and PROSTVAC through to mRNA-4157/V940, autogene cevumeran and TG4050.

Phase III case-study analysis

Detailed case studies of identified late-stage, industry-sponsored programmes, with clinical trial data referenced against the Provenge approval standard.

Cancer immunotherapy overview & dynamics

Active and passive immunotherapy strategies, checkpoint inhibitors and adoptive cell therapy, framed alongside the therapeutic vaccine category.

Disease burden & epidemiology

Updated global cancer burden data (GLOBOCAN 2022) and projections to 2050, positioned against this report's original 2012 WHO baseline.

Early decision-making support

Designed as an ideal tool to aid early-stage decision making in therapeutic cancer vaccine development, investment and market entry planning.

Sample analysis

A glimpse of the program-level model

The table below shows a partial view of the sponsor and mechanism framework. The full 300+ program dataset, phase-by-phase detail and revenue scenarios are in the licensed workbook.

SponsorMechanismTumour typePhaseRevenue scenario
Dendreon (Cenbest)Autologous dendritic cellProstate (mCRPC)ApprovedModelled
Moderna / MerckIndividualized neoantigen mRNAMelanomaPhase 3Modelled
BioNTech / Genentech-RocheIndividualized neoantigen mRNAPancreaticPhase 2Modelled
█████████████████████████$██m (base)
█████████████████████████$██m (upside)
Total addressable - baseAll mechanismsAll tumour typesAll phases$███m
Full model in the licensed workbook
300+ programs · to 2035 · all tumour types and mechanisms
Register interest →
Deliverables

What you receive

A comprehensive intelligence package combining a detailed executive presentation and a supporting Excel workbook, built for organisations evaluating the therapeutic cancer vaccine opportunity across the full immunotherapy landscape.

  • Executive presentation - cancer immunotherapy overview, global burden, target product profile considerations and full competitive environment review
  • MS-Excel workbook - the underlying dataset of 300+ verified cancer vaccine programs, delineated by sponsor, sponsor type, mechanism, tumour type and results
  • Phase III case studies - detailed profiles of identified late-stage, industry-sponsored programmes with clinical trial data referenced against the Provenge approval standard
  • Competitor intelligence - Provenge, PROSTVAC, mRNA-4157/V940, autogene cevumeran, TG4050 and the broader tracked pipeline
  • Updated epidemiology module - GLOBOCAN 2022 global burden data and projections to 2050, positioned against the original 2012 WHO baseline
  • Early decision-making support - a tool designed to aid early-stage decision making in therapeutic cancer vaccine investment and market entry planning
Target audience

Built for organisations evaluating the therapeutic cancer vaccine opportunity

Most valuable to teams assessing the therapeutic cancer vaccine landscape against their own pipeline, BD ambitions or investment thesis, drawing on VacZine Analytics' long standing expertise in chronic disease vaccine markets.

Vaccine & immunotherapy developers

Positioning, target product profile and commercial feasibility assessment for cancer vaccine candidates at any stage.

Corporate strategy & BD

Validate the size and structure of a market being reshaped by mRNA neoantigen technology, from Provenge's legacy through to the current registrational wave.

Investors & analysts

Independent assessment of pipeline risk and commercial upside for due diligence across Moderna, BioNTech, Transgene and the wider tracked field.

Public health & oncology policy

Disease burden modelling and immunotherapy landscape context to support future chronic disease programme planning.

Researchers & academia

Comprehensive epidemiology and R&D landscape for grant, translational and cancer immunotherapy planning.

Market access & policy

Pricing benchmarks and access-pathway context for cell-based and mRNA cancer vaccine reimbursement planning.

About this analysis · VAMV072

VacZine Analytics has long standing expertise in Chronic disease vaccine markets, positioning us to reassess the therapeutic cancer vaccine opportunity the moment mRNA technology reshaped what the category could deliver. This is a genuinely comprehensive analysis with a global program-level focus, spanning over 300 tracked Phase I-III programmes, and it has been well received by clients across the field for the depth of its competitive landscape and Phase III case-study review. Few groups have followed this field as closely across its full arc, from Provenge's approval through PROSTVAC's failure to the current neoantigen renaissance, and that recognised, independent expertise underpins everything in the analysis.

This report was last published in Feb 2017; any refresh would incorporate current GLOBOCAN 2022 global burden data, Provenge's current ownership and marketing status, PROSTVAC's confirmed discontinuation, and the current wave of mRNA-driven candidates led by Moderna/Merck's mRNA-4157/V940 and BioNTech's autogene cevumeran. The full syndicated MarketVIEW edition proceeds subject to sufficient client buy-in; where a faster or more tailored answer is required, VacZine Analytics can also be commissioned to deliver bespoke, ad-hoc analysis on this market.

MarketVIEW · VAMV072 · Syndicated & bespoke

Syndicate the refresh - or commission the answer you need

Register your interest to help shape and secure a full syndicated MarketVIEW refresh, which proceeds subject to sufficient client buy-in. Single-licence and multi-user options follow on publication. Need something faster or more specific? VacZine Analytics can be commissioned for bespoke, ad-hoc therapeutic cancer vaccine analysis, a briefing call is included on request.